Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE ...
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Everyone’s on Ozempic. So why will no one talk about it?
That Ozempic (or Wegovy, the name by which the weight-loss version of the drug semaglutide is marketed) should have proliferated in an industry that has always venerated thinness will hardly come as a ...
Ozempic is so popular people are trying to 'microdose' it. Is that a bad idea?
People are seeking out 'microdoses' of Ozempic and other weight-loss drugs. Medical professionals say there's pros and cons.
Let’s talk about semaglutide — is it safe, and who should consider it?
Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...
Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
Oklahoma's News16h
Competition explodes amid weight loss drug shortage
Novo Nordisk, the maker of the semaglutide products Ozempic and Wegovy, has filed lawsuits against 40 pharmacies, spas and ...
KELO17h
BioAge valued at $758 million in debut as investors bet on weight-loss drug frenzy
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
A weight loss drug developer's stock soars after a $198 million IPO
Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...
BioAge stock rallies 29% following upsized $198M IPO
BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.
An oral weight loss pill has just passed early trials with promising results—here's how it works
The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...